Prices for prescription drugs rose 2.3% in the first quarter of 1997, according to the research firm IMS America, Plymouth Meeting, PA.
Prices for prescription drugs rose 2.3% in the first quarter of 1997, according to the research firm IMS America, Plymouth Meeting, PA.
Although higher than previous increases - 1.8%, 2.0% and 1.8% in the second, third and fourth quarters of last year, respectively, - the growth is parallel with the current rate of inflation. The U.S. Bureau of Labor Statistics measured the consumer price index at 2.8% and the producer price index at 4.0% for all items in March 1997.
"While prices for some branded products accelerated, prices for most of the drugs manufacturers rely on for profit rose only modestly," said Robert N. Merold, IMS's vice president of marketing. "The overall pricing trend for pharmaceuticals is still in line with government pricing indexes."
Overall, the report showed that prices went up 2.9% compared with a year ago. Prices for branded drugs sold to retail pharmacies rose 4.6%, up from 3.9% last quarter, while prices of generic products fell at an annualized rate of 13.1%.
In the non-retail sector, which includes hospitals, clinics, HMOs and long-term care facilities, prices increased only 1.0% compared with last year. Staff-model HMOs led the growth at 3.4%, while federal facilities experienced a 2.4% decrease in prices.
Measured by dollar sales volume, the average price increases for the top 10 branded pharmaceutical products were significantly lower than the overall rates for other brands, according to the report.
The research firm concluded from the strong sales growth and modest price changes that price is not the engine driving market growth rates. Rather, new products, which are up 6.7%, and volume from existing products, which rose 4.3%, are stronger industry drivers. (For more information on industry drivers, see the article on page 8.) PR
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.